Unknown

Dataset Information

0

Chemical-genetic attenuation of focal neocortical seizures.


ABSTRACT: Focal epilepsy is commonly pharmacoresistant, and resective surgery is often contraindicated by proximity to eloquent cortex. Many patients have no effective treatment options. Gene therapy allows cell-type specific inhibition of neuronal excitability, but on-demand seizure suppression has only been achieved with optogenetics, which requires invasive light delivery. Here we test a combined chemical-genetic approach to achieve localized suppression of neuronal excitability in a seizure focus, using viral expression of the modified muscarinic receptor hM4Di. hM4Di has no effect in the absence of its selective, normally inactive and orally bioavailable agonist clozapine-N-oxide (CNO). Systemic administration of CNO suppresses focal seizures evoked by two different chemoconvulsants, pilocarpine and picrotoxin. CNO also has a robust anti-seizure effect in a chronic model of focal neocortical epilepsy. Chemical-genetic seizure attenuation holds promise as a novel approach to treat intractable focal epilepsy while minimizing disruption of normal circuit function in untransduced brain regions or in the absence of the specific ligand.

SUBMITTER: Katzel D 

PROVIDER: S-EPMC4050272 | biostudies-other | 2014 May

REPOSITORIES: biostudies-other

Similar Datasets

| S-EPMC4172478 | biostudies-literature
| S-EPMC4618174 | biostudies-literature
| S-EPMC4336552 | biostudies-literature
| S-EPMC7423163 | biostudies-literature
| S-EPMC4133160 | biostudies-literature
| S-EPMC9281624 | biostudies-literature
| S-EPMC3834227 | biostudies-literature
| S-EPMC5429237 | biostudies-literature
| S-EPMC9975184 | biostudies-literature
| S-EPMC4319118 | biostudies-literature